George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals, has played a pivotal role in transforming the company into one of the leading biopharmaceutical enterprises globally, driven primarily by scientific innovation rather than acquisitions. Since its founding nearly four decades ago, Regeneron has grown to a market value of approximately $70 billion, propelled by a robust pipeline of drugs and a portfolio boasting over 1,000 patents worldwide attributed to Yancopoulos.
Yancopoulos, 66, has been at the forefront of several groundbreaking therapies, including Eylea, an eye medication that has preserved sight for millions and accounted for a majority of Regeneron’s revenue during its peak. Another key product, Dupixent, approved in 2017, now treats nine allergic conditions and ranks as one of the most widely prescribed antibodies globally. However, recent challenges have emerged: Eylea faces growing competition, and Dupixent is expected to lose patent protection in the early 2030s. Additionally, the company’s stock has experienced a decline amid two late-stage drug development failures since early 2025.
Despite having more than $18 billion in cash reserves and many within the industry advocating for acquisitions, Yancopoulos emphasizes investing in internal research and development to sustain long-term growth. Regeneron currently has about 60 drug candidates under development, reflecting a diversified approach aimed at increasing the chances of success through multiple programs rather than banking on a single blockbuster. Yancopoulos stated that securing several smaller assets could be as valuable as landing one major breakthrough in the long run.
The scientist’s commitment to innovation was highlighted during a White House meeting in April, where Regeneron showcased its recent gene therapy designed to restore hearing in children affected by a rare genetic form of deafness. The company chose to make this treatment available free of charge in the United States, as a statement about the role of the pharmaceutical industry in delivering transformative medical advances.
Yancopoulos’ career in science began at an early age, inspired by personal experience. Growing up in Queens, New York, he was driven by a desire to address his grandmother’s battle with dementia. His academic journey led him through Columbia University, where he earned his bachelor’s degree, M.D., and Ph.D., and eventually to co-founding Regeneron alongside Leonard Schleifer, who manages the company’s business operations.
Today, Regeneron is focusing on a range of fields, including oncology and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. The company’s new state-of-the-art preclinical manufacturing facility in Tarrytown, New York, facilitates advanced research using genetically humanized mice and automated bioreactors. This scale-up represents a significant evolution from the company’s early days when Yancopoulos personally tended cell cultures in much more modest laboratory conditions.
In the competitive obesity treatment arena, Yancopoulos has taken a distinctive approach, targeting muscle preservation and the quality of weight loss rather than following a crowded market of GLP-1-based drugs. Regeneron is developing therapies that aim to protect muscle mass while reducing fat, thereby addressing risks associated with significant muscle loss, particularly in older populations. The company has also identified a genetic variant associated with sedentary behavior and is exploring a drug designed to modulate this "laziness gene" to promote increased calorie burning.
Through his scientific leadership, Yancopoulos has continuously pushed Regeneron to anticipate and create the next wave of therapeutic advances, sustaining the company’s reputation as an industry innovator.